114 related articles for article (PubMed ID: 38924865)
1. PLGA nanoparticle-delivered Leishmania antigen and TLR agonists as a therapeutic vaccine against cutaneous leishmaniasis in BALB/c mice.
Katebi A; Riazi-Rad F; Varshochian R; Ajdary S
Int Immunopharmacol; 2024 Jun; 138():112538. PubMed ID: 38924865
[TBL] [Abstract][Full Text] [Related]
2. Combinatorial delivery of antigen and TLR agonists via PLGA nanoparticles modulates Leishmania major-infected-macrophages activation.
Katebi A; Varshochian R; Riazi-Rad F; Ganjalikhani-Hakemi M; Ajdary S
Biomed Pharmacother; 2021 May; 137():111276. PubMed ID: 33485119
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the adjuvant effect of agonists of toll-like receptor 4 and 7/8 in a vaccine against leishmaniasis in BALB/c mice.
Rostamian M; Niknam HM
Mol Immunol; 2017 Nov; 91():202-208. PubMed ID: 28963929
[TBL] [Abstract][Full Text] [Related]
4. Vaccination with whole-cell killed or recombinant leishmanial protein and toll-like receptor agonists against Leishmania tropica in BALB/c mice.
Rostamian M; Bahrami F; Niknam HM
PLoS One; 2018; 13(9):e0204491. PubMed ID: 30248142
[TBL] [Abstract][Full Text] [Related]
5. Co-delivery of Dual Toll-Like Receptor Agonists and Antigen in Poly(Lactic-Co-Glycolic) Acid/Polyethylenimine Cationic Hybrid Nanoparticles Promote Efficient
Ebrahimian M; Hashemi M; Maleki M; Hashemitabar G; Abnous K; Ramezani M; Haghparast A
Front Immunol; 2017; 8():1077. PubMed ID: 28955328
[TBL] [Abstract][Full Text] [Related]
6. Vaccination with poly(D,L-lactide-co-glycolide) nanoparticles loaded with soluble
Margaroni M; Agallou M; Athanasiou E; Kammona O; Kiparissides C; Gaitanaki C; Karagouni E
Int J Nanomedicine; 2017; 12():6169-6184. PubMed ID: 28883727
[TBL] [Abstract][Full Text] [Related]
7. Nano-co-delivery of lipophosphoglycan with soluble and autoclaved leishmania antigens into PLGA nanoparticles: Evaluation of in vitro and in vivo immunostimulatory effects against visceral leishmaniasis.
Tosyali OA; Allahverdiyev A; Bagirova M; Abamor ES; Aydogdu M; Dinparvar S; Acar T; Mustafaeva Z; Derman S
Mater Sci Eng C Mater Biol Appl; 2021 Jan; 120():111684. PubMed ID: 33545846
[TBL] [Abstract][Full Text] [Related]
8. Towards development of novel immunization strategies against leishmaniasis using PLGA nanoparticles loaded with kinetoplastid membrane protein-11.
Santos DM; Carneiro MW; de Moura TR; Fukutani K; Clarencio J; Soto M; Espuelas S; Brodskyn C; Barral A; Barral-Netto M; de Oliveira CI
Int J Nanomedicine; 2012; 7():2115-27. PubMed ID: 22619548
[TBL] [Abstract][Full Text] [Related]
9. Identification of BALB/c Immune Markers Correlated with a Partial Protection to Leishmania infantum after Vaccination with a Rationally Designed Multi-epitope Cysteine Protease A Peptide-Based Nanovaccine.
Agallou M; Margaroni M; Athanasiou E; Toubanaki DK; Kontonikola K; Karidi K; Kammona O; Kiparissides C; Karagouni E
PLoS Negl Trop Dis; 2017 Jan; 11(1):e0005311. PubMed ID: 28114333
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of Th1 immune response against Leishmania cysteine peptidase A, B by PLGA nanoparticle.
Noormehr H; Zavaran Hosseini A; Soudi S; Beyzay F
Int Immunopharmacol; 2018 Jun; 59():97-105. PubMed ID: 29649772
[TBL] [Abstract][Full Text] [Related]
11. TLR-2 agonist Pam3CSK4 has no therapeutic effect on visceral leishmaniasis in BALB/c mice and may enhance the pathogenesis of the disease.
Liao X; He J; Wang R; Zhang J; Wei S; Xiao Y; Zhou Q; Zheng X; Zhu Z; Zheng Z; Li J; Zeng Z; Chen D; Chen J
Immunobiology; 2023 Sep; 228(5):152725. PubMed ID: 37562277
[TBL] [Abstract][Full Text] [Related]
12. Leishmania tarentolae secreting the sand fly salivary antigen PpSP15 confers protection against Leishmania major infection in a susceptible BALB/c mice model.
Katebi A; Gholami E; Taheri T; Zahedifard F; Habibzadeh S; Taslimi Y; Shokri F; Papadopoulou B; Kamhawi S; Valenzuela JG; Rafati S
Mol Immunol; 2015 Oct; 67(2 Pt B):501-11. PubMed ID: 26298575
[TBL] [Abstract][Full Text] [Related]
13. Immunization against leishmaniasis by PLGA nanospheres loaded with an experimental autoclaved Leishmania major (ALM) and Quillaja saponins.
Tafaghodi M; Eskandari M; Kharazizadeh M; Khamesipour A; Jaafari MR
Trop Biomed; 2010 Dec; 27(3):639-50. PubMed ID: 21399606
[TBL] [Abstract][Full Text] [Related]
14. Induction of protection against leishmaniasis in susceptible BALB/c mice using simple DOTAP cationic nanoliposomes containing soluble Leishmania antigen (SLA).
Firouzmand H; Badiee A; Khamesipour A; Heravi Shargh V; Alavizadeh SH; Abbasi A; Jaafari MR
Acta Trop; 2013 Dec; 128(3):528-35. PubMed ID: 23916506
[TBL] [Abstract][Full Text] [Related]
15. Transcutaneous immunization using SLA or rLACK skews the immune response towards a Th1 profile but fails to protect BALB/c mice against a Leishmania major challenge.
Lakhal-Naouar I; Koles N; Rao M; Morrison EB; Childs JM; Alving CR; Aronson NE
Vaccine; 2019 Jan; 37(3):516-523. PubMed ID: 30528328
[TBL] [Abstract][Full Text] [Related]
16. Polylactide Nanoparticles as a Biodegradable Vaccine Adjuvant: A Study on Safety, Protective Immunity and Efficacy against Human Leishmaniasis Caused by Leishmania Major.
Ayari-Riabi S; Ben Khalaf N; Bouhaouala-Zahar B; Verrier B; Trimaille T; Benlasfar Z; Chenik M; Elayeb M
Molecules; 2022 Dec; 27(24):. PubMed ID: 36557812
[TBL] [Abstract][Full Text] [Related]
17. Cross-protective effect of a combined L5 plus L3 Leishmania major ribosomal protein based vaccine combined with a Th1 adjuvant in murine cutaneous and visceral leishmaniasis.
Ramirez L; Corvo L; Duarte MC; Chávez-Fumagalli MA; Valadares DG; Santos DM; de Oliveira CI; Escutia MR; Alonso C; Bonay P; Tavares CA; Coelho EA; Soto M
Parasit Vectors; 2014 Jan; 7():3. PubMed ID: 24382098
[TBL] [Abstract][Full Text] [Related]
18. Identification of Immunodominant Antigens From a First-Generation Vaccine Against Cutaneous Leishmaniasis.
Germanó MJ; Mackern-Oberti JP; Vitório JG; Duarte MC; Pimenta DC; Sanchez MV; Bruna FA; Lozano ES; Fernandes AP; Cargnelutti DE
Front Immunol; 2022; 13():825007. PubMed ID: 35634280
[TBL] [Abstract][Full Text] [Related]
19. Angelica sinensis polysaccharide encapsulated into PLGA nanoparticles as a vaccine delivery and adjuvant system for ovalbumin to promote immune responses.
Gu P; Liu Z; Sun Y; Ou N; Hu Y; Liu J; Wu Y; Wang D
Int J Pharm; 2019 Jan; 554():72-80. PubMed ID: 30399435
[TBL] [Abstract][Full Text] [Related]
20. Pam3CSK4 adjuvant given intranasally boosts anti-Leishmania immunogenicity but not protective immune responses conferred by LaAg vaccine against visceral leishmaniasis.
Salgado CL; Dias EL; Stringari LL; Covre LP; Dietze R; Lima Pereira FE; de Matos Guedes HL; Rossi-Bergmann B; Gomes DCO
Microbes Infect; 2019; 21(7):328-335. PubMed ID: 30817996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
